Where does Kancera AB rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Kancera AB ranks #18,802 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Kancera AB hold?

Kancera AB holds 15 US utility patents granted between 2015 and 2025, spanning 8 technology areas.

What is Kancera AB's Innovation Score?

Kancera AB has an Innovation Score of 38.7 out of 100 (top 40% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Kancera AB focus on?

Kancera AB's top technology area is C07D (Heterocyclic Compounds) with 10 patents, ranking #819 of 3,165 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is Kancera AB's patent grant rate increasing or decreasing?

Kancera AB's recent grant velocity is +33% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Kancera AB's patents?

Kancera AB's patents average 18.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Kancera AB patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Kancera AB

USPTO PatentsView assignee record - 15 granted patents across 8 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Kancera ranks #18,802 of 49,997 tracked US assignees by granted-patent volume, with 15 patents across 8 technology areas.

#18,802
of 49,997 US assignees by volume: Top 40%
by Innovation Score (38.7/100): 18.0
avg claims per patent: +33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R18802 · Foreign Corporation #18,802 · 15 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-UP · BOOK-FULL

GRANTS-MICRO 15 grants
MID-PACK #18,802/49,997
PHOTO-FINISH Yoshikawakuni Kogyosho
CPC-NARROW C07D · 8 areas
INNOV-THIN 38.7/100
CLAIMS-RICH 18.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-UP +33% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Kabushiki Kaisha Yoshikawakuni Kogyosho (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Kancera’s 38.7 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.6 pts (25%) Velocity 8.3 pts (21%) Breadth 10.0 pts (26%) Claim depth 10.8 pts (28%)

Qualcomm Incorporated · highest

85
Kancera AB · this assignee

39
3D Lighting… · lowest

7

What this shows Kancera's Innovation Score is 38.7/100 (top 40% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Kancera?

Each dot is one of Kancera’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Kancera’s own 18.0 claims/patent is ABOVE the 12.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Kancera vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Kancera's grants concentrate

Kancera AB is a focused PatentsView assignee: 8 CPC subclasses with 66.7% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2023 (3 grants) versus a trough of 1 in 2015. By volume, Kancera sits between Kyodo Printing Co., Ltd. and Komatsu Forest AB.

Kancera's three-year grant acceleration

Kancera AB shows 5 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Kyodo Printing

15
Kyowa Medex

15
Yoshikawakuni Kog…

15
Kakaobank

15
Kesseböhmer Holdi…

15
Kineticor

15
Knowmtech

15
Komatsu Forest AB

15
Kancera AB ◀

15

What this shows Kancera holds 15 patents at rank #18,809, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Kancera

By rank, the assignees closest to #18,809 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Kancera's primary technology class.

Kancera's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

39 Top 40% higher than 60% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Kancera AB patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	6.7%
2016	2	13.3%
2017	1	6.7%
2018	1	6.7%
2019	1	6.7%
2020	2	13.3%
2021	1	6.7%
2022	1	6.7%
2023	3	20.0%
2024	1	6.7%
2025partial year	1	6.7%

Which technologies does Kancera AB patent most?

C07D - Heterocyclic Compounds 10

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 8

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

C07C - Acyclic OR Carbocyclic Compounds 3

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 2

C07K - Peptides 2

C12Y - Enzymes 1

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Kancera AB's patent record in context - here's where to go next.

Kancera AB's lead technology class is C07D (Heterocyclic Compounds), 66.7% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #18,802 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Kancera AB against Kyodo Printing Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 38.7/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.